Treatment of Latent Tuberculosis Infection Based on the Interferon-γ Release Assay in Allogeneic Stem Cell Transplant Recipients

Joung Ha Park; Eun-Ji Choi; Han-Seung Park; Sang-Ho Choi; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee; Tae Sun Shim; Sung-Han Kim

doi:10.1093/cid/ciaa030

Treatment of Latent Tuberculosis Infection Based on the Interferon-γ Release Assay in Allogeneic Stem Cell Transplant Recipients

Clin Infect Dis. 2020 Nov 5;71(8):1977-1979. doi: 10.1093/cid/ciaa030.

Authors

Affiliations

¹ Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
² Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
³ Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

PMID: 31930297
DOI: 10.1093/cid/ciaa030

Abstract

In hematopoietic stem cell transplant recipients, the incidence of tuberculosis in positive interferon-γ release assay (IGRA) without isoniazid prophylaxis (3.58/100 person-years) was higher than in negative or indeterminate IGRA (1.15/100 person-years; P = .01) and in positive IGRA with isoniazid prophylaxis (0/100 person-years; P = .09). The number needed to treat was 22 (95% confidence interval, 12-99) with positive IGRA results.

Keywords: hematopoietic stem cell transplant; interferon-γ release assay; latent tuberculosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Interferon-gamma Release Tests
Latent Tuberculosis* / diagnosis
Latent Tuberculosis* / drug therapy
Stem Cell Transplantation / adverse effects
Transplant Recipients
Tuberculin Test